Drug Database
CA

calcitonin (Calsynar / calcitonin, Aventis / Calcin)

✓ Approved

Sanofi S.A · CALCR · 多肽类

什么是 calcitonin?

calcitonin 是一种多肽类,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled。

药物档案

商品名Calsynar, calcitonin, Aventis, Calcin
公司Sanofi S.A
药物类别多肽类
分子靶点CALCR
给药途径Inhaled
状态Approved

作用机制

分子靶点

calcitonin 作用于 1 个分子靶点:

CALCRcalcitonin receptor (CT-R, CTR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

calcitonin 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresHypercalcaemia therapy✓ Approved
Musculoskeletal and connective tissue disordersOsteitis deformans✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

相关研究文献

PubMedJournal of medical case reports2026-11-19

Rapid progression of myocardial calcification in a patient presenting with hypercalcemia of unidentified etiology: a case report.

Hirai Shota S, Nishigaito Toshiya T, Mitsumoto Kensuke K, Mizumoto Aya A et al.

Myocardial calcification is an uncommon but clinically important finding that may result in severe cardiac dysfunction. It is generally classified as metastatic calcification triggered by an elevated serum calcium-phosphate product or dystrophic calcification occurring at sites of prior inflammatory or ischemic injury. There are few reports describing dynamic changes in myocardial calcification among patients with hypercalcemia. In addition, hypercalcemia with an unidentified cause has rarely been reported. We encountered a fatal case that developed both metastatic and dystrophic myocardial calcification. This case may contribute to a better understanding of the potential cardiac complications of severe hypercalcemia.Affiliations: Journal instruction requires a city and country for affiliations; however, these are missing in affiliation [2, 3]. Please verify if the provided city and country are correct and amend if necessary.All authors' affiliation addresses are Osaka, Japan. A 57-year-old Japanese woman with a history of asthma presented with nausea and fatigue. She had severe hypercalcemia with acute kidney injury and marked eosinophilia. Intact parathyroid hormone was suppressed (11 pg/mL), with normal parathyroid hormone-related protein and vitamin D metabolites. Fractional excretion of calcium was elevated to 12%. Imaging studies, bone marrow examination, and renal biopsy did not identify a definitive etiology. She was diagnosed with severe hypercalcemia of unidentified etiology complicated by acute kidney injury and eosinophilia. Despite intravenous fluids, calcitonin, and denosumab followed by hemodialysis, she developed progressive respiratory failure and circulatory collapse with myocardial injury and coronary microvascular dysfunction, and serial CT showed new myocardial calcification from day 9 with rapid diffuse progression. She died 22 days after admission despite extracorporeal circulatory support, and autopsy revealed extensive multi-organ calcification including the heart and lungs. Severe hypercalcemia of unidentified etiology can be complicated by extensive myocardial calcification. Ectopic calcification initially induced by hypercalcemia may have been influenced by inflammatory conditions such as eosinophilia. In addition, subsequent myocardial injury may accelerate dystrophic calcification. Clinicians should be aware of the risk of early and progressive cardiac involvement in patients with hypercalcemia, particularly in the presence of inflammatory conditions.

PMID 43053195
阅读全文 →
PubMedMedical oncology (Northwood, London, England)2026-11-18

CGRP-CALCRL-VEGFR signaling promotes angiogenesis and cervical cancer progression.

Lu Jing J, Li Siqi S, Han Qi Q, Maisaidi Reyilanmu R et al.

Neuro-tumor crosstalk is increasingly recognized as a fundamental driver of cancer progression. Calcitonin gene-related peptide (CGRP), a neuropeptide classically associated with sensory neurons, has emerged as a key mediator of tumor growth, immune suppression, and cancer-associated symptoms across multiple malignancies. However, the role of CGRP signaling in cervical cancer remains poorly defined. We comprehensively analyzed CGRP expression and its clinical relevance in cervical cancer using TCGA transcriptomic datasets, gene correlation analyses, and survival models. Single-cell RNA sequencing data were leveraged to define the cellular distribution of the CGRP receptor calcitonin receptor-like receptor (CALCRL). In HUVECs, CALCRL was silenced by siRNA and evaluated using proliferation, tube-formation, gene-expression, rescue, and signaling assays, including exogenous α-CGRP stimulation and VEGFR1/VEGFR2 overexpression. In vivo, CGRP-receptor inhibition was evaluated in SiHa, CaSki, and HeLa xenograft models using Fremanezumab or olcegepant. Elevated CGRP expression was associated with adverse prognosis in TCGA-CESC, and independent clinical validation showed that high CALCB expression was associated with poorer survival (log-rank P = 0.0036). Single-cell transcriptomic analyses consistently revealed that CALCRL expression was highly enriched in endothelial cells. CALCRL silencing impaired endothelial proliferation and angiogenic capacity, whereas exogenous α-CGRP enhanced these phenotypes in control cells but not in CALCRL-silenced cells. VEGFR1 or VEGFR2 overexpression partially rescued the proliferation defect caused by CALCRL depletion. Pharmacological inhibition of CGRP-receptor signaling consistently suppressed tumor growth across SiHa, CaSki, and HeLa xenograft models. These findings provide preclinical evidence that CGRP-CALCRL signaling promotes cervical cancer progression through endothelial angiogenic activity and VEGFR-associated signaling, supporting further investigation of this pathway as a potential therapeutic target.

PMID 43049824
阅读全文 →
PubMedExpert opinion on biological therapy2026-11-18

Real-world effectiveness and safety of eptinezumab in migraine prevention.

Pellesi Lanfranco L, Scuteri Damiana D, Allamprese Rossana R, Guerzoni Simona S et al.

Eptinezumab is the only anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered intravenously for migraine prevention. Randomized trials have shown efficacy in episodic and chronic migraine, including after previous preventive failures, but strict eligibility criteria limit their generalizability to routine care. This review summarizes the pharmacology and pivotal trials of eptinezumab and examines real-world studies of its effectiveness and safety, identified through a PubMed search up to October 2026. Particular attention is given to patients with previous anti-CGRP antibody failure, medication overuse and cardiovascular disease, and to the limitations of the available evidence. Real-world cohorts confirm a rapid onset and a clinically relevant benefit in broader and more refractory populations, with mostly mild and transient adverse events, although hypersensitivity reactions during infusion deserve attention. Effect sizes vary widely and are likely inflated by analyses restricted to patients who remain on treatment. Previous response to an antibody may predict benefit better than previous failure. Priorities are controlled switching studies, predictors of response and prospective evidence on when to judge treatment and whom to escalate to 300 mg.

PMID 43046757
阅读全文 →
PubMedExpert review of clinical pharmacology2026-11-18

TRPM8 channel blockers as a potential new pharmacological class for the treatment of migraine.

Pellesi Lanfranco L, Chiarugi Alberto A, Kupferman Justine J, Crutchlow Michael M et al.

Migraine therapy has advanced in recent years, particularly with the emergence of calcitonin gene-related peptide (CGRP)-targeting drugs. However, acute treatment still faces limitations, especially in patients who are unresponsive to or unable to take triptans or gepants. Transient receptor potential melastatin 8 (TRPM8) is a polymodal-gated, nonselective cation channel that represents a promising target for the treatment of migraine supported by genetic, preclinical and clinical evidence. This review covers the evidence supporting an important role for TRPM8 in the pathophysiology of migraine and provides a detailed synopsis of the preclinical, pharmacodynamic and pharmacokinetic profiles of potential TRPM8-interacting compounds in clinical development for the treatment of migraine. PubMed and ClinicalTrials.gov were searched to August 2026 for TRPM8 and migraine, supplemented by 2026 congress abstracts and company disclosures. TRPM8 channel blockade has a mechanistically distinct approach from current therapeutics. A proof-of-concept and dose range finding Phase 2 study with elismetrep, a novel, oral TRPM8 blocker, provides supportive, although not definitive, evidence for TRPM8 blockers in migraine. Although the primary endpoint of 2-hour pain freedom was not statistically significant, numerically greater effects at 20 mg and nominally significant secondary-endpoint findings support further development.

PMID 43046674
阅读全文 →
PubMedBioscience reports2026-11-18

Sulfo‑DIBMA encapsulation uniquely preserves signalling‑competent active states of Class B1 GPCRs, CGRP and PTH1 receptors in native‑like nanodiscs.

Napier-Khwaja Farhaan F, Gunner Joseph J, Thacker Ellie E, Abdolhay Yasaman Y et al.

Class B1 G‑protein‑coupled receptors (GPCRs), such as the calcitonin gene‑related peptide (CGRP) receptor and parathyroid hormone 1 (PTH1) receptor, require native lipid interactions to maintain signalling‑competent conformations. However, conventional detergents disrupt these environments. Amphipathic copolymers offer a detergent‑free alternative, yet the field still lacks a clear understanding of which polymer architectures best preserve active‑state GPCR pharmacology, limiting their broader translational utility. Here, we examine how distinct copolymer chemistries influence the functional integrity of class B1 GPCRs by comparing SMA 2000, DIBMA‑12, and the electroneutral sulfo‑DIBMA. Using NanoLuciferase bioluminescence resonance energy transfer (NanoBRET) ligand-binding, competition, and mini‑G‑protein recruitment assays on nanodisc-encapsulated receptors, we show that all three copolymers maintain high‑affinity extracellular ligand binding but differ markedly in their ability to preserve intracellular signalling. Despite lower receptor extraction efficiency, only sulfo‑DIBMA supports mini‑Gαs engagement at the CGRP receptor and enable G‑protein‑dependent allosteric modulation at the PTH1 receptor, including conserved ligand affinity and prolonged residence time. These data reveal that polymer charge and backbone chemistry, rather than extraction yield, determine whether native-like nanodiscs retain the conformational landscape required for active‑state signalling. Controlling non-specific ligand binding to the copolymer is a key requirement for a successful assay. Our findings identify sulfo‑DIBMALP as a particularly superior environment for preserving native signalling behaviour in class B1 GPCRs, highlighting copolymer chemistry as an important determinant in detergent‑free membrane protein studies.

PMID 43049705
阅读全文 →
PubMedNeurology and therapy2026-11-18

Implementing Intravenous Eptinezumab in Routine Migraine Care: A Mixed-Methods Study of Patient and Healthcare Professional Perspectives.

Anukoolwittaya Prakit P, Hiransuthikul Akarin A, Sinchai Kanokwan K, Payuha Tanabodee T et al.

Eptinezumab is a calcitonin gene-related peptide monoclonal antibody (CGRP mAb) for migraine prevention, offering rapid onset and quarterly intravenous administration. However, evidence regarding patient and healthcare professional (HCP) experiences and its implementation in routine practice remains limited. This study has explored the opportunities and challenges of eptinezumab treatment. This convergent mixed-methods study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. A total of 20 patients with migraine who received eptinezumab and 10 HCPs participated. Monthly headache days (MHDs) and Migraine Disability Assessment (MIDAS) scores were evaluated over 6 months for patients. Semi-structured in-depth interviews explored experiences with eptinezumab treatment for both participant groups, with transcripts analyzed using thematic analysis. Median MHDs decreased from 18.5 (IQR 8.5-28.0) at baseline to 5.0 (2.0-8.0) at Month 3 and 2.5 (1.0-5.0) at Month 6. Median MIDAS scores decreased from 63.5 (30.0-77.5) to 15.0 (1.0-33.0) and 5.0 (0.5-19.5), respectively. Qualitative findings identified three opportunities: improved migraine symptoms and quality of life, favorable treatment experience and acceptability, and addressing unmet needs in patients with migraine who had experienced multiple preventive treatment failures. Patients and HCPs described improved migraine control, restored daily functioning, and favorable tolerability. Three major challenges emerged: financial and access barriers, health-system and service delivery challenges, and treatment-related concerns. High costs and limited reimbursement were the predominant barriers identified by both participant groups. Patients and HCPs perceived eptinezumab as an effective and well-accepted preventive treatment. Although quarterly intravenous administration was viewed favorably, financial barriers and healthcare system constraints remain major obstacles to broader implementation. These findings offer practical insights into integrating CGRP-targeting therapies into routine care. NCT07035197 (ClinicalTrials.gov).

PMID 43049833
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多calcitonin